Bipolar Depression: Diagnosis Confirmed, Next Steps?
neuroscienceCME Webcast
Premiere Date: Tuesday, February 24, 2015This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, February 24, 2016
Note: Credit Is No Longer Available
 | Roger S. McIntyre, MD, FRCPC University of Toronto University Health Network Toronto, ON Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA) Chicago, IL Clinical Professor, Department of Psychiatry and Neurosciences University of California School of Medicine Riverside, CA |
 | Rodrigo B. Mansur, MD Clinical/Research Fellow in Psychiatry University of Toronto Mood Disorders Psychopharmacology Unit University Health Network Toronto, ON |
Bipolar disorder is a complex, chronic, psychiatric condition for which long-term therapy and ongoing clinical monitoring is critical. Bipolar depression presents special challenges for treatment. A significant percentage of time is spent in a depressed mood as compared to mania, hypomania, or euthymia. One of the challenges in treating bipolar depression is that all mood disorders are not alike, and clinicians need to think differently about their approach to its clinical management. Medications that work in unipolar depression, such as antidepressants, are not necessarily appropriate in bipolar depression and remain controversial because in some cases, patients taking SSRIs have switched into hypomania. While many various agents are used to treat mania, there are only three second generation antipsychotics (SGAs) that are FDA-approved for bipolar depression.1 Another layer of complexity for clinical management is that most SGAs have been shown to precipitate weight gain, hyperglycemia, and metabolic syndrome. Clinicians have not been consistent or proactive in monitoring patients for metabolic issues.2
This unique neuroscienceCME Clinical Consult presents a “fly on the wall” perspective of a clinical consult with junior faculty discussing a complex case of bipolar depression with a senior faculty member to gain broader insight and expertise to better establish a partnership with patients to improve outcomes.
- Beyer JL, Ketter, TA, McIntyre RS, Suppes T. Managing bipolar depression: an evidence-based approach. Current Psychiatry. 2013;12(10 Suppl):S1-S8. No PMID.
- McElroy SL, Keck PE Jr. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014;75(1):46-61. PMID: 24502861.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Monitor bipolar depression patients for metabolic changes at least every three months.
At the end of this CE activity, participants should be able to:
- Develop a partnership with patients with bipolar depression to establish treatment goals and integrate effective strategies to monitor therapeutic goals and evaluate and concurrently manage comorbidities.
- Implement strategies to optimize long-term pharmacological management and comprehensive assessment of metabolic risk of bipolar depression.
This activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc.
Psychiatrists, physicians, pharmacists, and other health care professionals who treat individuals with bipolar disorder.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .75 contact hours (0.075 CEUs)
Universal Activity Number: 0376-0000-15-009-H01-P
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST1985 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre has received grant/research support from the National Alliance for Research on Schizophrenia and Depression (NARSAD); National Institutes of Mental Health; Stanley Medical Research Institute; AstraZeneca; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck; Pfizer Inc.; and Shire. He serves on the speakers bureau for Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck; Merck & Co., Inc.; and Pfizer Inc.. He is on the advisory boards of AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; The France Foundation; GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck; Merck & Co., Inc.; Organon; Pfizer Inc.; and Shire.
Dr. Mansur has nothing to disclose.
Tony Graham, MD (content/peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-065-022415-23
